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Abstract
Background: Chronic heart failure (CHF) is a global public health problem. Therefore, novel and effective drugs that show
few side-effects are needed. Early literature studies indicated that Huangqi injection is one of the most commonly used
traditional Chinese patent medicines for CHF in China. As a large number of clinical studies has been carried out and
published, it is essential to evaluate the effectiveness and safety of Huangqi injection. Therefore, we carried out this
systematic review under the support of the framework of the Joint Sino-Italian Laboratory (JoSIL).
Objectives: To evaluate the efficacy and safety of Huangqi injection for CHF according to the available scientific knowledge.
Methods: An extensive search including PubMed, EMBASE, CBM, the Cochrane Library and Chinese literature databases was
performed up to July 2008. Clinical trials regarding Huangqi injection for the treatment of CHF were searched for,
irrespective of languages. The quality of each trial was assessed according to the Cochrane Reviewers’ Handbook 5.0, and
RevMan 5.0 provided by the Cochrane Collaboration and STATA 9.2 were used for data analysis.
Results: After selection of 1,205 articles, 62 RCTs and quasi-RCTs conducted in China and published in Chinese journals were
included in the review. The methodological quality of the trials was low. In most trials inclusion and exclusion criteria were
not specified. Furthermore, only one study evaluated the outcomes for drug efficacy after an adequate period of time. For
these reasons and because of the different baseline characteristics we did not conduct a meta-analysis.
Conclusions: Although available studies are not adequate to draw a conclusion on the efficacy and safety of Huangqi
injection (a traditional Chinese patent medicine), we hope that our work could provide useful experience on further studies
on Huangqi injections. The overall level of TCM clinical research needs to be improved so that the efficacy of TCM can be
evaluated by the international community and possibly some TCM can enter into the international market.
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Introduction
Chronic heart failure (CHF) is the end-stage of various heart
diseases that arise for many reasons. The American Heart
Association (AHA) hasdefined CHFas a complex clinical syndrome
that can result from any structural or functional cardiac disorder
that impairs the ability of the ventricle to fill with or eject blood [1].
A Report from the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee indicates that
heart failure (HF) incidence approaches 10 per 1,000 of the
population over 65 years of age. After HF is diagnosed, survival
rates are lower in men than in women, but fewer than 15% of
women survive more than 8 to 12 years. The estimated direct and
indirect cost of HF in the United States in 2008 is $34.8 billion [2].
The European Society of Cardiology (ESC), representing
countries with a population of over 900 million, estimates at least
10 million patients with HF in these countries. The prognosis of
HF is uniformly poor if the underlying problem cannot be
rectified. Half of the patients carrying a diagnosis of HF will die
within 4 years, and more than half of those with severe HF will die
within 1 year [3].
In 2000, the United States, China, Australia and Thailand
jointly carried out an international cooperation research program
on cardiovascular disease in Asia (InterASIA). The adult
population sampled was collected from 10 Provinces in China
(five in the north, and five in the south). The urban and rural
populations accounted for 50% of each, as did the proportion of
males to females. The results showed that, on a total of 15,518
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19604adults surveyed (35–74 years old) the prevalence of CHF was 0.9%
for the general population, 0.7% for the males, and 1.0% for the
females. The risk of CHF was higher in northern than southern
China (P,0.01) and was higher in urban than rural areas [4].
The AHA, the ESC and other international organizations have
actively developed and updated the guidelines for the diagnosis
and management of CHF, in order to provide evidence for the
diagnosis and treatment of HF [1,3]. At present, the effectiveness
of conventional treatments for CHF has been proven (e.g.
angiotensin converting enzyme (ACE) inhibitors, b-blockers and
diuretics). Despite several therapeutic approaches in CHF
management have led to an important reduction of cardiovascular
morbidity and mortality, CHF remains the only cardiovascular
disease with an increasing hospitalization burden and an ongoing
drain on health care expenditures [5]. Therefore, it remains
necessary to seek novel effective drugs.
In some ‘‘traditional’’ medicines plant derived products may
have a therapeutic use in heart failure treatment. A systematic
review on Hawthorn has reported a significant benefit in symptom
control and physiologic outcomes as an adjunctive treatment for
CHF [6]. Studies on animal models of human disease suggest that
resveratrol has the potential to decrease cardiovascular symptoms
in patients with myocardial and cardiomyopathies [7]. Curcumin
may protect against the pathological changes occurring with
atherosclerosis [8], and the potential therapeutic use of cannabi-
noids in heart failure has been studied [9].
A previous non-systematic review of the literature to individuate
TCM herbs used for treatment of CHF was performed from some
of the authors of this review, many Chinese patent medicines and
traditional prescriptions (decoctions of Chinese herbs) were listed.
Among the others, Huangqi injection was seen to be one of the
most commonly used Chinese patent medicines for the treatment
of CHF in clinical practice [10] as complementary treatment to
recommended Western therapies. So we decided to perform a
systematic review on Huangqi injection for CHF.
Huangqi injection is a preparation of an extract of Radix
Astragali: the major components are astragalosides [11], and the
other pharmacological ingredients include polysaccharides, fla-
vones and amino acids. Modern pharmacological research has
shown that Huangqi injection can enhance myocardial contrac-
tility, improve circulation, protect myocardial cells and regulate
immunity [12,13].
Astragalus membranaceus (Fisch) Bge var. Mongolicus (Bge) Hsiao,
is a typical Traditional Chinese Medicine plant, used as food, and
present since many years on the Western market (in Europe and
USA) as food supplement. Astragalus membranaceus has being used
for thousands of years in China and East Asia also for kidney
diseases, and in modern Chinese medicine, it seems to have renal
protective effect in diabetic nephropathy [14].
The extract of the Astragalus root is usually used also in
Western phytotherapy as galenic preparations, containing dried
extract standardized in polysaccharides, the substances that are
mostly considered responsible for the presumed immunostimulant
properties [15]: it is in particular used for recurrent respiratory
diseases or as therapeutic complement in cancer treatment [16].
To date, a large number of clinical studies have been reported
in the literature. We have here carried out a systematic review to
evaluate the effectiveness and safety of Huangqi injection for CHF
in a joint Sino-Italian collaboration.
Traditional Chinese Medicine (TCM) has been used for many
centuries, and it is still widely used today in countries of south and
east Asia for the treatment of people with CHF.
With the purpose of investigating the appropriate scientific
evidence for some specific TCM the Italian National Institute of
Health and the Tianjin University of Traditional Chinese
Medicine have implemented a common project, the Joint Sino-
Italian Laboratory (JoSIL) on TCM. This systematic review was
conducted within the framework of JoSIL.
Methods
Types of studies
Randomized and quasi randomized clinical trials (RCTs) to
evaluate Huangqi injection for CHF up to July 2008 were
searched, irrespective of languages. With the term ‘‘quasi-RCT’’
we intend trials that use methods to allocate patients such as
alternation, case record numbers, dates of birth, etc. For these
trials there is a greater risk of selection bias compared with RCTs.
Types of participants
Trials including adult patients with CHF were eligible,
irrespective of the etiology. CHF had to be diagnosed according
to the ACC/AHA 2005 Guidelines for the Diagnosis and
Management of CHF, or according to the corresponding
diagnostic criteria in China [1,17]. Trials that included patients
with acute-HF were excluded.
Types of interventions
We included in our review only trials that tested Huangqi
injection plus conventional treatments versus conventional treat-
ments alone for CHF. The studies that used hospital preparations
of Huangqi injection were excluded. Trials in which the type of
preparation was not specified (either from a pharmaceutical
company or hospital) were included.
Study selection
To identify all of the relevant studies, an extensive search was
performed in July 2008. We searched the Cochrane Central
Register of Controlled Trials (2008, issue 3), PubMed (1950–
2008), EMBASE (1985–2008) and the Chinese Biomedical
Database (1978–2008). We also searched other Chinese journal
databases (Chinese Journal Full-Text Database (1979–2008),
Chinese Science and Technology Journal Database (1989–2008)
and Wanfang Data Info Site) to identify theses and conference
articles. To reduce omissions, we made an extensive electronic
database search, followed by handsearch. The keywords were
‘‘Huangqi OR mongolian milkvetch root OR Astragalus membranaceus
OR astragalus extract OR Radix Astragali’’ AND ‘‘chronic heart
failure, cardiac dysfunction, cardiac inadequacy, cardiac insuffi-
ciency, heart insufficiency, ventricular dysfunction, cardiac failure,
myocardial failure, congestive heart failure, heart decompensa-
tion’’. These terms were used as free-text terms (translated into
Chinese) to search some of the Chinese databases. Free-text and
MeSH terms were used to search PubMed and Cochrane Library.
Free-text and Emtree terms were used to search EMBASE. We
also checked the references of published studies to identify
additional trials.
Two reviewers (SF, JZ) independently examined the titles and
abstracts of the trials for inclusion, based on the selection criteria
outlined above. The full texts of articles were retrieved if there was
any doubt whether an article should be included or not.
Inconsistencies were solved through discussion. The selected trials
that were claimed to be randomized were retrieved and then
examined for confirmation that they were indeed correctly
randomized. A table with the English translation of all the titles
and the English abstract was reviewed by other two investigators
(MM, FMI).
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A quality assessment was carried out for all the retrieved studies.
Quality in a systematic review essentially refers to the absence of
biases.
The main biases in a clinical trial can derive from systematic
differences between comparison groups in: measured or unmea-
sured baseline characteristics because of the way participants were
selected or assigned (selection bias); care provided apart from the
intervention being evaluated (performance bias); how outcomes
are ascertained, diagnosed or verified (detection bias); withdrawals
or exclusions of participants from the results of a study (attrition
bias).
To assess the methodological validity of the studies included in
this review the following aspects were evaluated (according to a
binary score presence/absence): randomization, allocation con-
cealment, blinding and description of follow-up. According to
Cochrane reviewers’ Handbook [18] three categories were
defined: A-all quality criteria met: (low risk of bias); B-one or
more of the quality criteria only partly met (moderate risk of bias);
C-one or more criteria not met (high risk of bias).
Articles were assessed by two reviewers (JZ and SF) indepen-
dently. Disagreements were resolved by consultation with a third
reviewer (XG).
Data extraction
The information on patients, methods, interventions, outcomes
and results was extracted and summarized by two reviewers (SF
and JZ) independently using a standardized data extraction form.
Disagreements were resolved through discussion among all
Chinese investigators. For dichotomous outcomes, the number of
responders and the total number of participants for each study
arm were extracted. For continuous outcomes (e.g. left ventricular
ejection fraction), the mean change and standard deviation for the
mean in each group of the trial were extracted along with the total
number.
Data analysis
In this study, statistical analysis was performed using software
provided by the Cochrane Collaboration (Review Manager 5.0)
[19] and STATA 9.2 software [20].
For measurement data, we took the differences before and after
treatment for statistical analysis. Dichotomous data are presented
as rate ratio, while continuous data are expressed as mean
difference (MD), all with 95% confidence intervals (CI). A funnel
plot was used to investigate potential publication bias.
Results
Search flow
According to the search strategy we identified 1,205 potentially
relevant studies. By reading titles and abstracts, we excluded 728
studies that were clearly duplicates, review articles, case reports or
non-clinical studies.
After the full text reading, 369 articles were excluded because
non-RCT or patients not satisfying the inclusion criteria. Twenty
were excluded because the intervention did not meet the inclusion
criteria and 4 because of not reliable data. The improvement of
the New York Heart Association (NYHA) classification or the Left
Ventricular Ejection Fraction (LVEF) were considered as
outcomes in seventy five (89%) of the remaining 84 trials. For
these reasons only trials reporting these outcomes were analyzed.
Thirteen trials were excluded because the baseline data for
outcome measures (NYHA classification and LVEF) was not
available (Figure 1).
The baseline characteristics (e.g. sex, age, course of disease) of
the patients included in the trials reporting NYHA classification
and LVEF were described only in 62 trials. The following results
are only related to these trials (Table S1) [21–82].
We did not consider other outcomes such as cardiac output,
speed of ventricular diastolic filling, left ventricular volume, heart
rate, systolic and diastolic blood pressure or other cardiovascular
endpoint because less frequently listed in the trials and not so well
described. No trial had any evaluation of Quality of Life. All of the
included studies were carried out in China over the past 14 years
(1995–2008). Sixteen of these studies had an English abstract and
two of them were conference articles [39,75]. All of these studies
indicated randomization, but most of them were quasi-RCTs with
a single-center, parallel-design.
Characteristics of the trials included
The number of participants included in each of the studies
ranged from 30 to 140 (only one study included 532 patients), with
a total of 5,548 patients (2,950 patients in the investigational
groups) in the 62 studies. The mean proportion of males present in
the trials was 63.3%. The age of the participants ranged from 18
years to 89 years, with a mean age of 60.9 years. Fifty-eight studies
mentioned the etiology (12 studies only included patients with
pulmonary HF). Twenty-one studies reported the duration of the
disease: from one month to 28 years.
In seven of the trials, the inclusion criteria were specified, and in
three the exclusion criteria were defined. Only four of the trials
reported a description of all the subjects selection criteria (e.g.
diagnostic, inclusion criteria, exclusion criteria). The criteria of
terminationand completion were not mentioned in any ofthe studies.
Five studies, among the 62, reported mortality data.
All patients included in the trialswerenot in an acute exacerbation
of CHF, and they were hospitalized to prevent acute exacerbation of
CHF. During these non-acute admissions the trials were conducted.
The studies included interventions with Huangqi injection plus
routine treatments versus routine treatments alone. Routine
treatments referred to treatment according to the guidelines for
CHF, including cardiotonics, diuretics, Angiotensin II receptor
blockers (ARBs), (ACE) inhibitors and b-blockers [1,3]. Thirty six
studies mentioned the brand of the Huangqi injections, which
were from five pharmaceutical companies. Nine studies clarified
the lot number of the Huangqi injection and 23 studies described
the doses conversion relationship between the injection and the
medical herbs. The doses of Huangqi injection used ranged from
10 ml to 60 ml. The duration of treatment ranged from 7 days to
30 days, with a median treatment duration of 14 days. A variety of
outcome measures were reported. The evaluation of the outcomes
was performed at the end of the treatment. Only in 2 trials the
follow up period was mentioned (from 3 to 6 months).
Methodological quality
All of the studies included indicated randomization, with three
of the trials reporting that the random sequence was generated by
a random digits table, and four by the patient treatment order. No
trial described allocation concealment. Two of the trials
mentioned that they were single blind, but included no
descriptions of the procedures. Two of the trials described
withdrawals with no intention-to-treat analyses. None of the trials
described any methods of assessing compliance.
The analysis was only focused on trials that considered as
outcome measure an improvement of at least one class on the
NYHA classification or on the LVEF. These outcomes were
chosen because they were considered the most relevant for a
clinical point of view in the evaluation of the effectiveness of drugs.
Huangqi Injection for Chronic Heart Failure
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poor. In most trials inclusion and exclusion criteria were not
specified. Furthermore, only one study evaluated the outcomes for
drug efficacy after an adequate period of time. There was not any
study of sufficient quality that could be highlighted.
For these reasons and because of the different baseline
characteristics we did not conduct a meta-analysis.
Effectiveness
The ‘‘effective rate’’ (ER) was the most commonly used
measure to evaluate efficacy. In 49 studies where this measure
was reported an ‘‘effective rate ratio’’ (ERR) was calculated as the
ratio between the proportion of responders in the treatment
group and the proportion of responders in the control group. The
responders were defined as an improvement of at least one class
on the NYHA classification. In 35 trials responders were defined
as improvements of NYHA classification and some TCM
symptoms (such as coated tongue, color of lips, cough and
edema). Since ER reported in the trials considering NYHA
classification with or without some TCM symptoms were similar
we did not present separate figures for the two groups of studies.
The other outcome measure was the LVEF. The mean difference
(MD) of LVEF before and after the study treatment was
measured in 23 studies. The effect measure was estimated as
the mean difference in the intervention and control groups. In 10
studies both outcomes were considered.
NYHA classification
As illustrated in figure 2, forty-nine trials with 4,584 patients
(2,435 patients in the active treatment group) selected as outcome
measure an improvement of at least one class on the NYHA
classification. For this indicator 25 studies were statistically
significant, showing that Huangqi injection plus routine treatment
can improve cardiac function and clinical symptoms. There was
not statistically significance in the other 24 studies.
LVEF
LVEF is the ratio of the stroke volume and the left ventricular
end-diastolic volume. It is frequently used for the assessment of HF
and for the evaluation of drug efficacy. Twenty-three studies
reported the outcomes for LVEF. Seventeen studies showed that
Huangqi injection combined with routine treatment was better
than routine treatment used alone for the increase in LVEF, while
six studies were not statistical significant (Figure 3).
Other outcomes
Five [55,62,76,77,82] of the 62 studies reported the mortality
data. Though mortality is a very important indicator, these studies
Figure 1. Flow diagram of the article selection for this study.
doi:10.1371/journal.pone.0019604.g001
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reported the causes very imprecisely. Furthermore, the studies
were not designed for the evaluation of mortality as primary
outcome.
Safety analysis
Adverse events were not mentioned in 30 of the studies (48.4%).
Twenty-eight studies (45.2%) reported that no adverse reactions
were seen at the end of treatment. In four studies, various adverse
Figure 2. Effective rate analysis based on improvements of classification in NYHA.
doi:10.1371/journal.pone.0019604.g002
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patients in the test group.
The side-effects in the routine treatment group included dry cough
(4/47), bradycardia (2/47), low blood pressure (2/47) and digitalis
poisoning (6/36). The main side effects related to Huangqi injection
were mainly discomfort of the gastrointestinal tract. Three studies
[35,64] reported dizziness, and facial flushing as side effects, with a
rate of 5.9% (7/118). Three patients reported mild nausea in two
studies [64,74], with an incidence rate of 3.8% (3/80). After treatment
or slowing down of the intravenous drip, the patients recovered.
Funnel plot
Funnel plots based on the data for the ERRs and MD of LVEF
were elaborated in Figure 4. The figures are asymmetrical
indicating that potential publication bias might influence the
results of this review.
Figure 3. Data analysis of left ventricular ejection fraction.
doi:10.1371/journal.pone.0019604.g003
Figure 4. Funnel plots of ERR (A) and LVEF Mean Difference (B).
doi:10.1371/journal.pone.0019604.g004
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Limitation of our review was the underlying concern about the
quality of the included studies.
In our systematic review, in fact, it was not possible to find well-
designed trials to evaluate the efficacy of Huangqi injection for
CHF, and, thus, meta-analysis was not performed.
All the trials use an A+B versus B design where patients are
randomized to receive a control treatment (the Control Group)
versus a control treatment plus the experimental treatment (the
Treatment Group). This kind of design is likely to generate false
positive results [83].
Formal inclusion/exclusion criteria were reported only in
22.6% of the studies. Baseline information on disease duration
was available only in 21 trials. None of the trials included provided
information on clinical stability of the patients recruited in the
weeks preceding trial recruitment. Furthermore, no information
on persistence on previous treatments is available in any of the
studies included and it can not be excluded that in some of the
participants routine treatment began concomitantly with Haungqi
treatment. The lack of baseline information may lead to selection
bias and not comparable baseline.
In general we considered not reasonable in our review to
calculate a pooled average result across studies because of their
high clinical heterogeneity (i.e. dissimilarity in disease severity,
previous episodes of medical care, co-morbidities, co-interven-
tions, etc).
Another common shortcoming was the inadequate description
of the randomisation procedures. Although all trials claimed to
have performed randomization, only three trials reported the
method to generate the allocation sequence (random digits table)
and the remaining trials did not give any details of the
randomization method. Blinding was mentioned in two trials
without describing the methods of allocation concealment. Thus,
whether the randomization was effectively conducted in these
trials was doubtful. Inappropriate randomization or allocation
concealment can lead to selection bias. Not controlling for
blinding could deal with an overestimation of the effect of the
experimental treatment, unless the assessment of the outcome is
performed by a researcher not involved in the treatments
allocation. All trials were conducted only in one clinical centre.
Dropout cases were reported in three trials and were not
mentioned in the others. It was not clear whether these trials
had any dropout cases or whether they were simply not reported.
Having dropout cases without reporting can result in attrition bias.
Only 51.6% of the studies described the occurrence of adverse
events.
As far as the quality of Huangqi preparations are concerned,
even though the studies that adopted hospital preparations were
excluded from our review, 26 of the included studies did not
mention the source of the Huangqi injection. Quality control of
herbal preparations is crucial for the critical appraisal of the results
in this kind of studies. In order to assess the efficacy of a specific
product in a clinical study, all participants should be given exactly
the same intervention in terms of product identity, purity, dosage
and formulation.
From a clinical standpoint, only 5 of the studies included in our
revision approached important end-points such as mortality, but
the causes were not clearly reported. All the trials were actually
focussed on ancillary or surrogate outcomes. The evaluation of
clinical symptoms through the classification system of the New
York Heart Association is subject to placebo effect and moreover
most of the included studies were not blinded. Although
ventricular dysfunction is the hallmark of low output cardiac
failure, hemodynamic data, such as ejection fraction, should be
regarded as supportive only. Changes in various invasive and non-
invasive measures of ventricular performance have not shown to
correlate closely with each other and many of them do not
correlate with clinical symptoms or functional capacity [84]; for
these reasons the value of these measures in evaluating the efficacy
of drugs in patients with cardiac failure during long-term
treatment is very limited [84].
In all the trials the duration of therapy and follow-up was indeed
too short to allow to achieve conclusive results. Only in 2 trials
included in our review there was a follow-up period (range 3–6
months) duration, while in the other studies the outcomes were
evaluated only at the end of the treatment (range 7–30 days). In
order to evaluate drug efficacy for CHF, long-term improvement
(at least 6 months) of CHF-specific clinical symptoms is needed
[84]. Some drug classes have shown to increase mortality in the
long-term application despite a short term improvement in clinical
symptoms [84].
Adverse events were reported only in 50% of trials, indicating
an incomplete evaluation of the safety profile of Huangqi injection,
as well as a poor quality in the reporting.
Overall, because of the poor methodological quality of the
studies, the results of the trials included in this systematic review
are likely to be influenced by many biases. Furthermore, since the
review included only articles published on the Chinese literature
and no primary articles reporting negative results were found, a
location bias cannot be excluded (i.e. trials published in low or
non-impact factor journals are more likely to report significant
results than those published in high-impact mainstream medical
journals).
Some research on TCM could move to an efficacy-driven
approach. Randomized, controlled trials, when appropriately
designed, conducted, and reported, represent the gold standard
in evaluating health care interventions.
Well-designed and properly conducted RCT provides high-
quality ‘‘raw materials’’ for conducting systematic reviews and
health technology assessment. Poorly designed and reported trials
usually exaggerate the treatment effects which will mislead clinical
decision making.
In 2008, Xu et al assessed the randomized clinical trials
published in the five leading Chinese medical journals indexed by
MEDLINE and found that only 22 articles (15.5%) reached a high
quality grade (.=3 points) according to the Jadad scale [85].
Randomized clinical trials in TCM area often show method-
ological weaknesses: absence of sample size estimation, failure in
use (or reporting) randomization as well as unclear study objective
and hypothesis are common [86,87].
Because of the low methodological quality of trials and selective
publication of positive results, the efficacy of most traditional
therapies remains at the best uncertain.
Journals in China should obey international criteria for
publication (such as CONSORT, STROBE, PRISMA, etc) and
require documentation of ethics approval and clinical trial
registration before manuscript acceptance.
Ethical issues are increasingly gaining attention from Chinese
researchers. However, in the studies included in our SR ethical
issues were not mentioned. Only one study [65] mentioned that
the informed consent was obtained.
Chinese Government has made research into traditional
medicine a priority area and, with funding increasing by 20% a
year, China now has more investment in research and develop-
ment than any other country except the USA [88,89]. Chinese
regulations and guidelines do not substantially differ from those in
Europe or the USA but their implementation in daily research and
Huangqi Injection for Chronic Heart Failure
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with international standards.
International collaboration should be encouraged, promoted
and financed from the governments in order to improve research.
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